Bioengineer Gang Bao uses gene editing to repair up to 40 percent of bone marrow cells from patients
Scientists have successfully used gene editing to repair 20 to 40 percent of stem and progenitor cells taken from the peripheral blood of patients with sickle cell disease, according to Rice University bioengineer Gang Bao.
Bao, in collaboration with Baylor College of Medicine, Texas Children’s Hospital and Stanford University, is working to find a cure for the hereditary disease. A single DNA mutation causes the body to make sticky, crescent-shaped red blood cells that contain abnormal hemoglobin and can block blood flow in limbs and organs.
In his talk at the annual American Association for the Advancement of Science meeting in Austin Feb. 16, Bao revealed results from a series of tests to see whether CRISPR/Cas9-based editing can fix the mutation. His presentation was part of a scientific session titled “Gene Editing and Human Identity: Promising Advances and Ethical Challenges.”
“Sickle cell disease is caused by a single mutation in the beta-globin gene (in the stem cell’s DNA),” he said. “The idea is to correct that particular mutation, and then stem cells that have the correction would differentiate into normal blood cells, including red blood cells. Those will then be healthy blood cells.”
Bao’s lab collaborated with Vivien Sheehan, an assistant professor of pediatrics and hematology at Baylor and a member of the sickle cell program at Texas Children’s, to collect stem and progenitor cells (CD34-positive cells) from patients with the disease. These were then edited in the Bao lab with CRISPR/Cas9 together with a custom template, a piece of DNA designed to correct the mutation.
The gene-edited cells were injected into the bone marrow of immunodeficient mice and tested after 19 weeks to see how many retained the edit. “The rate of repair remained stable, which is great,” Bao said. This engraftment study was carried out in the lab of Matt Porteus, an associate professor of pediatrics at Stanford.
Another major finding of the study is that the CRISPR/Cas9 system could introduce large alterations to the genes in patients’ cells, in addition to small mutations or deletions. These off-target effects could cause a disease.
The findings, part of an upcoming paper, are a step toward treating sickle cell disease. Obstacles in the way of a cure include optimizing the CRISPR/Cas9 system to eliminate off-target effects, as well as finding a way to further increase the amount of gene-corrected stem cells.
Bao pointed out that researchers still don’t know whether repairing as much as 40 percent of the cells is enough to cure a patient. “We’d like to say, ‘Yes,’” he said, “but we don’t really know yet. That’s something we hope to learn from an eventual clinical trial.”
The Latest on: Sickle cell disease
- Addressing Disparities in the Care of People with Sickle Cell Disease on November 13, 2018 at 6:07 am
For the 100,000 Americans with sickle cell disease, the majority of whom are African-American, most days mean coping with the complications and consequences of their chronic disease. In addition ... […]
- Sickel Cell: 200 children screened in Ojodu on November 12, 2018 at 6:53 pm
She said children with SS can survive and live a healthy life when they are given adequate care. The medical practitioner defined Sickle Cell disease as an abnormality in the blood. The symptoms of Si... […]
- Omi Woods draws inspiration from matriarchal line, raises awareness for sickle cell anemia on November 12, 2018 at 12:08 am
Sickle cell anemia is a genetic disorder caused by abnormalities in red blood cells, in the hemoglobin gene. Anyone can suffer from this disease but it is commonly diagnosed in people from African ... […]
- Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer Cell Lines at San Antonio Breast Cancer Symposium on November 9, 2018 at 12:01 pm
Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep e... […]
- Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price on November 8, 2018 at 10:34 am
"We felt we needed to control our own destiny." The commitment by Global Blood is tied to its hope that regulators will accelerate approval of the company's treatment for sickle cell disease. If that ... […]
- SU and Sickle Cell Association host blood and bone marrow drive on November 8, 2018 at 7:47 am
to host a Sickle Cell Disease blood and bone marrow drive on Wednesday, November 7. Students, employees, and community members answered the call to come and be a donor for someone in need. This drive ... […]
- Sickle Cell Foundation Partner Rhieos Ventures to Develop First Multi-center Registry on November 7, 2018 at 7:34 pm
... cell disorder and the registry will be used to support and improve quality of treatment and care for persons with Sickle Cell Disease (SCD), as well as for policy formulation around sickle cell de... […]
- Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease on November 6, 2018 at 11:31 pm
STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational ... […]
- Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation on November 5, 2018 at 8:09 am
The abstracts reported data from the clinical program for the treatment of severe sickle cell disease, the analyst said. Since June 15, eight patients have received treatment in the Phase 1 study. “Th... […]
- Global Sickle Cell Disease Treatments Market Growth Analysis 2018 on November 2, 2018 at 8:43 am
MarketResearchNest.com presents “Global Sickle Cell Disease Treatments Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023” new Research to its studies database. The record... […]
via Google News and Bing News